Abstract:Introduction: Liver cancer (LC) is frequently preceded by cirrhosis and poses a significant public health challenge in the United States (US). Recent decades have seen notable shifts in the epidemiological patterns of LC, yet national data guiding the optimal allocation of resources and preventive efforts remain limited. This study aims to investigate the current trends, risk factors, and outcomes of LC in the US. Methods: This study utilized the Global Burden of Disease (GBD) dataset to collect data on the annual incident cases, deaths, Disability-Adjusted Life Years (DALYs), age-standardized incidence rates (ASIR), age-standardized death rates, and age-standardized DALY rates of primary LC and its etiologies and risk factors, between 1990 and 2019. Percentage changes in incident cases, DALYs, and deaths and the estimated annual percentage change (EAPC) in ASIR and deaths rates of LC were calculated to conduct temporal analysis. Linear regression was applied for the calculation of EAPCs. Correlations of EAPC with socio-demographic index (SDI) were separately evaluated by Pearson correlation analyses. Results: We observed a marked increase in the ASIR of LC, increasing from 2.22 (95% CI: 2.15-2.27) per 100,000 people in 1990 to 5.23 (95% CI: 4.28-6.29) per 100,000 people in 2019, a percentage change of 135.4%. LC due to hepatitis C followed by alcohol use were the primary factors driving this increase. The ASIR and age-standardized death rates of LC showed a significant average annual increase of 3.0% (95% CI: 2.7-3.2) and 2.6% (95% CI: 2.5-2.8), respectively. There was a significant negative correlation between the SDI and the EAPC in ASIR (ρ = -0.40, p = 0.004) and age-standardized death rates (ρ = -0.46, p < 0.001). In 2019, drug and alcohol use, followed by elevated body mass index (BMI) were the primary risk factors for age-standardized DALY rates attributable to LC. Conclusion: The increased burden of LC in the US highlights the need for interventions. This is particularly important given that LC is mostly influenced by modifiable risk factors, such as drug and alcohol use, and elevated BMI. Our findings highlight the urgent need for public health interventions targeting socio-economic, lifestyle, and modifiable risk factors to mitigate the escalating burden of LC.

Global Trends and Inequalities of Liver Complications Related to Metabolic Dysfunction‐Associated Steatotic Liver Disease: An Analysis From 1990 to 2021

S2006 Temporal Trends and Regional Disparities in the Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) From 1980 to 2021: An Analysis of GBD Study 2021

Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019

The Burden of Liver Cirrhosis and Underlying Etiologies: Results from the Global Burden of Disease Study 2019

Metabolic Dysfunction-associated Steatotic Liver Disease is Becoming the Leading Driver of the Burden of Cirrhosis in China: Results From the Global Burden of Disease Study 2019

Burden of Liver Complications Related to Non‐alcoholic Fatty Liver Disease in China from 2005 to 2019: Observations from the Global Burden of Disease Study, 2019

Global burden trends of MAFLD‐related liver cancer from 1990 to 2019

Global burden of nonalcoholic steatohepatitis-related liver cancer, 1990–2019: a systematic analysis for the GBD 2019

Current status and future trends of the global burden of MASLD

Global burden of metabolic dysfunction-associated steatotic liver disease attributable to high fasting plasma glucose in 204 countries and territories from 1990 to 2021

Examining the evolving landscape of liver cancer burden in the United States from 1990 to 2019

Metabolic Syndrome and Metabolic Dysfunction-Associated Steatotic Liver Disease in Premenopausal Women: Global Trends and Projections to 2040

Epidemiology of liver diseases: global disease burden and forecasted research trends

Association of Food Insecurity with the Prevalence and Liver-related Mortality of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Global Epidemiology of Early-Onset Liver Cancer Attributable to Specific Aetiologies and Risk Factors from 2010 to 2019.

Worldwide burden of liver cancer due to metabolic dysfunction-associated steatohepatitis from 1990 to 2019: insights from the Global Burden of Disease study

Burden of liver cancer due to hepatitis C from 1990 to 2019 at the global, regional, and national levels

Attributable liver cancer deaths and disability-adjusted life years in China and worldwide: profiles and changing trends

Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease

Global, Regional, and National Burden of Liver Cancer Due to Non-Alcoholic Steatohepatitis, 1990–2019: a Decomposition and Age–period–cohort Analysis

The burden of liver cirrhosis in mortality: Results from the global burden of disease study